Jennifer Wang

3.6k total citations · 1 hit paper
67 papers, 1.9k citations indexed

About

Jennifer Wang is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Surgery. According to data from OpenAlex, Jennifer Wang has authored 67 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Endocrinology, Diabetes and Metabolism, 22 papers in Oncology and 15 papers in Surgery. Recurrent topics in Jennifer Wang's work include Thyroid Cancer Diagnosis and Treatment (28 papers), BRCA gene mutations in cancer (9 papers) and Head and Neck Cancer Studies (8 papers). Jennifer Wang is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (28 papers), BRCA gene mutations in cancer (9 papers) and Head and Neck Cancer Studies (8 papers). Jennifer Wang collaborates with scholars based in United States, Canada and China. Jennifer Wang's co-authors include Stephen Y. Lai, Maria E. Cabanillas, Mark Zafereo, Naifa L. Busaidy, Ramona Dadu, Verna J. Higgins, Michelle D. Williams, Renata Ferrarotto, Jonathan D. Smith and Chris Lominska and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature Biotechnology.

In The Last Decade

Jennifer Wang

56 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes

2021 413 citations Jennifer Wang, Stephen Y. Lai et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer Wang United States	21	694	612	554	288	274	67	1.9k
Vasyl Vasko United States	21	882 1.3×	602 1.0×	659 1.2×	293 1.0×	200 0.7×	38	1.7k
Fatima Rangwala United States	14	421 0.6×	557 0.9×	618 1.1×	159 0.6×	177 0.6×	34	1.6k
Joshua Klopper United States	17	1.5k 2.1×	580 0.9×	750 1.4×	245 0.9×	423 1.5×	34	2.2k
Valentina Sancisi Italy	22	489 0.7×	360 0.6×	816 1.5×	290 1.0×	122 0.4×	33	1.5k
Donata Vitagliano Italy	19	587 0.8×	1.0k 1.7×	920 1.7×	228 0.8×	163 0.6×	29	1.9k
Minjing Zou Saudi Arabia	30	1.0k 1.5×	638 1.0×	1.1k 1.9×	221 0.8×	389 1.4×	71	2.1k
Vasily Vasko United States	18	1.4k 2.0×	954 1.6×	1.2k 2.2×	259 0.9×	389 1.4×	21	2.4k
Iñigo Landa United States	24	1.9k 2.7×	983 1.6×	1.0k 1.9×	406 1.4×	602 2.2×	46	3.0k
Cristina Montero‐Conde Spain	20	542 0.8×	389 0.6×	585 1.1×	321 1.1×	177 0.6×	31	1.3k
Hiroshi Sonoo Japan	26	335 0.5×	1.3k 2.2×	820 1.5×	645 2.2×	476 1.7×	123	2.3k

Countries citing papers authored by Jennifer Wang

Since Specialization

Citations

This map shows the geographic impact of Jennifer Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Wang more than expected).

Fields of papers citing papers by Jennifer Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Wang. The network helps show where Jennifer Wang may publish in the future.

Co-authorship network of co-authors of Jennifer Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Wang. A scholar is included among the top collaborators of Jennifer Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Wang. Jennifer Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cabanillas, Maria E., Naifa L. Busaidy, G. Brandon Gunn, et al.. (2025). Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer. Thyroid. 35(7). 763–770. 1 indexed citations

Bernstein, Eric F., et al.. (2025). Safety and Effectiveness of a New 532 nm, Long Pulse‐Duration, Variable Pulse Structure Laser for Treatment of Poikiloderma of Civatte. Lasers in Surgery and Medicine. 57(2). 171–176.

Salim, Hamza, Ahmed Msherghi, Kim O. Learned, et al.. (2025). Prognostic Factors in Thyroid Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. Thyroid. 35(12). 1378–1390.

Dadu, Ramona, Priyanka Iyer, Naifa L. Busaidy, et al.. (2025). Circulating Tumor DNA as a Biomarker for Disease Surveillance in Anaplastic Thyroid Cancer. JCO Precision Oncology. 9(9). e2500067–e2500067.

Learned, Kim O., Jennifer Wang, Xiao Zhao, et al.. (2024). [¹⁸F]-FDG Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma followingBRAF-Targeted Therapy. American Journal of Neuroradiology. 46(6). 1260–1267.

Dadu, Ramona, Naifa L. Busaidy, Renata Ferrarotto, et al.. (2024). Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 6106–6106. 3 indexed citations

Bernstein, Eric F., et al.. (2024). The 2910‐nm Fiber Laser Is Safe and Effective for Improving Acne Scarring. Lasers in Surgery and Medicine. 56(9). 755–761. 1 indexed citations

Li, Sophie H., Guibin Zheng, Li Xu, et al.. (2024). Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid Carcinoma. JAMA Otolaryngology–Head & Neck Surgery. 151(2). 113–113. 1 indexed citations

Iyer, Priyanka, Ramona Dadu, Maria Gule-Monroe, et al.. (2024). Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF ^V600E -Mutated Anaplastic Thyroid Carcinoma. Thyroid. 34(3). 336–346. 34 indexed citations

10.

Lesluyes, Tom, Toby M. Baker, Maxime Tarabichi, et al.. (2024). Reconstructing oral cavity tumor evolution through brush biopsy. Scientific Reports. 14(1). 22591–22591.

11.

Dadu, Ramona, Mark Zafereo, Renata Ferrarotto, et al.. (2024). Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer. JAMA Oncology. 10(9). 1264–1264. 12 indexed citations

12.

Charles‐Schoeman, Christina, Jennifer Wang, Ani Shahbazian, et al.. (2023). Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis. Rheumatology International. 43(6). 1041–1053. 3 indexed citations

13.

Charles‐Schoeman, Christina, et al.. (2023). Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. The Journal of Rheumatology. 50(12). 1573–1580. 3 indexed citations

14.

Wang, Jennifer, et al.. (2023). Current and future opportunities for the management of primary biliary cholangitis. SHILAP Revista de lepidopterología. 2. 1241901–1241901.

15.

Wang, Jennifer, Xu Li, Maitrayee Goswami, et al.. (2022). Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precision Oncology. 6(6). e2100504–e2100504. 45 indexed citations

16.

Hahn, Andrew W., Jad Chahoud, Matthew T. Campbell, et al.. (2021). Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Investigational New Drugs. 39(5). 1405–1410. 37 indexed citations

17.

Qin, Yu, Jennifer Wang, Ying Wang, et al.. (2021). Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid. 31(8). 1235–1243. 34 indexed citations

18.

Cabanillas, Maria E., Ramona Dadu, Naifa L. Busaidy, et al.. (2020). Acquired Secondary RAS Mutation in BRAF ^V600E -Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid. 30(9). 1288–1296. 68 indexed citations

19.

Ren, Jianjun, Wei Xu, Jie Su, et al.. (2019). Multiple imputation and clinico‐serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable. International Journal of Cancer. 146(8). 2166–2174. 9 indexed citations

20.

Wang, Jennifer, Mark Zafereo, Ramona Dadu, et al.. (2019). Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF ^V600E -Mutated Anaplastic Thyroid Carcinoma. Thyroid. 29(8). 1036–1043. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact